Locally Advanced Unresected Head And Neck Squamous Cell Carcinoma
ANABAnaptyBio IncCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Jemperli/Dostarlimab (PD-1 Antagonist) in Locally Advanced Unresected Head And Neck Squamous Cell Carcinoma. The expected timing is based on the latest available company guidance and may change.
11/04/25:- JADE pivotal Ph3 trial of dostarlimab monotherapy vs placebo in locally advanced unresected HNSCC; data TBA. 03/03/26:- JADE pivotal Ph3 HNSCC trial ongoing; topline data expected in 2028. 05/12/26:- GSK highlights JADE pivotal Ph3 HNSCC trial, with data expected in 2028.
Verification
Confirm timing and program details against the company announcement or filing.